Surgical Science Sweden AB (publ)
Surgical Science Sweden AB (publ) (SUSRF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Surgical Science Sweden AB (publ) (SUSRF), featuring income statements, balance sheets, and cash flow data.
Surgical Science Sweden AB (publ) (SUSRF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Surgical Science Sweden AB (publ) SUSRF financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $251.55M | $231.83M | $212.47M | $188.24M |
| Cost of Revenue | $81.47M | $70.82M | $82.91M | $79.29M |
| Gross Profit | $170.07M | $161.01M | $129.55M | $108.96M |
| Gross Profit Ratio | $0.68 | $0.69 | $0.61 | $0.58 |
| R&D Expenses | $51.66M | $50.58M | $48.84M | $40.24M |
| SG&A Expenses | $72.24M | $60.66M | $63.29M | $46.63M |
| Operating Expenses | $130.95M | $115.23M | $110.05M | $86.87M |
| Total Costs & Expenses | $212.42M | $186.04M | $179.04M | $166.16M |
| Interest Income | $295000.00 | $0.00 | $4.38M | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $16.62M | -$1000.00 | $0.00 | $14.87M |
| EBITDA | $55.75M | $45.78M | $33.43M | $25.98M |
| EBITDA Ratio | $0.22 | $0.20 | $0.16 | $0.14 |
| Operating Income | $39.13M | $45.79M | $33.43M | $22.09M |
| Operating Income Ratio | $0.16 | $0.20 | $0.16 | $0.12 |
| Other Income/Expenses (Net) | $295000.00 | $7.24M | $4.38M | $1.86M |
| Income Before Tax | $39.42M | $53.02M | $37.81M | $27.84M |
| Income Before Tax Ratio | $0.16 | $0.23 | $0.18 | $0.15 |
| Income Tax Expense | $3.16M | $10.002M | $9.24M | $4.05M |
| Net Income | $36.26M | $43.02M | $28.57M | $23.79M |
| Net Income Ratio | $0.14 | $0.19 | $0.13 | $0.13 |
| EPS | $0.71 | $0.84 | $0.56 | $0.47 |
| Diluted EPS | $0.71 | $0.84 | $0.56 | $0.47 |
| Weighted Avg Shares Outstanding | $51.03M | $51.03M | $51.03M | $51.03M |
| Weighted Avg Shares Outstanding (Diluted) | $51.03M | $51.03M | $51.03M | $51.03M |
Over the last four quarters, Surgical Science Sweden AB (publ)'s revenue moved from $188.24M in Q1 2024 to $251.55M in Q4 2024. Operating income in Q4 2024 was $39.13M, with a strong operating margin of 16%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Surgical Science Sweden AB (publ) remained robust at $55.75M, reflecting operational efficiency. Net income dropped to $36.26M, with an EPS of $0.71. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan